Trials / Completed
CompletedNCT00822484
Study Evaluating Single Doses of ILV-095 in Healthy Japanese Male Subjects
Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ILV-095 Administered Subcutaneously to Healthy Japanese Male Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (actual)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- Male
- Age
- 20 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the safety and tolerability of single doses of ILV-095 in healthy Japanese male subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | ILV-095 | |
| OTHER | Placebo |
Timeline
- Start date
- 2009-02-01
- Primary completion
- 2009-09-01
- Completion
- 2009-09-01
- First posted
- 2009-01-14
- Last updated
- 2011-05-06
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT00822484. Inclusion in this directory is not an endorsement.